Megestrol acetate for cachexia-anorexia syndrome. A systematic review

Area of Science:

• Pharmacology
• Clinical Medicine
• Systematic Reviews

Background:

• Megestrol acetate (MA) is FDA-approved for treating anorexia and cachexia in AIDS patients.
• The mechanism of MA's appetite-stimulating effect remains unclear.
• Effectiveness of MA for anorexia-cachexia in various patient groups is under ongoing investigation.

Purpose of the Study:

• To systematically review the efficacy and safety of megestrol acetate for treating anorexia-cachexia syndrome.
• To update previous Cochrane reviews on MA for anorexia-cachexia.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials.
• Comparisons included MA versus placebo, MA versus no treatment, MA versus active drugs, and different doses of MA.
• Outcomes assessed were weight gain, quality of life (QOL), adverse events, and mortality.

Main Results:

• MA significantly increased weight compared to placebo (MD 2.25 kg) and active drugs (MD 2.5 kg), but not compared to no treatment.
• No significant improvements in quality of life were observed across comparisons.
• MA was associated with more adverse events than placebo (RR 1.46) but not compared to no treatment or active drugs.
• No significant differences in mortality were found when comparing MA to placebo, no treatment, or active drugs.
• No significant differences in weight gain, QOL, or adverse events were found between different doses of MA.

Conclusions:

• Megestrol acetate promotes weight gain in patients with anorexia-cachexia syndrome.
• MA does not appear to improve quality of life and may increase adverse events compared to placebo.
• Further research is needed to determine the optimal dosage and long-term effects of MA.